HC Wainwright Lifts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright upped their Q4 2025 earnings per share estimates for TG Therapeutics in a report released on Wednesday, January 14th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of $0.27 for the quarter, up from their prior estimate of $0.20. HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2027 earnings at $1.92 EPS.

A number of other brokerages also recently weighed in on TGTX. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. The Goldman Sachs Group boosted their target price on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, December 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.75.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $30.57 on Friday. The firm’s 50 day simple moving average is $30.77 and its 200 day simple moving average is $32.53. The firm has a market capitalization of $4.85 billion, a price-to-earnings ratio of 11.00 and a beta of 1.86. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. TG Therapeutics has a 1 year low of $25.28 and a 1 year high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The business had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. During the same quarter in the prior year, the business posted $0.02 earnings per share. TG Therapeutics’s revenue was up 92.7% compared to the same quarter last year.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently modified their holdings of the business. Ameritas Advisory Services LLC purchased a new position in shares of TG Therapeutics in the second quarter worth approximately $25,000. Johnson Financial Group Inc. bought a new position in TG Therapeutics in the second quarter worth approximately $25,000. Danske Bank A S bought a new position in TG Therapeutics in the third quarter worth approximately $25,000. Optiver Holding B.V. boosted its stake in shares of TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 486 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In related news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the sale, the director directly owned 223,816 shares in the company, valued at $7,289,687.12. This trade represents a 2.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is currently owned by company insiders.

Trending Headlines about TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Seeking Alpha published an upgrade/positive piece that highlights accelerating commercial momentum and investor “exit velocity,” supporting a more bullish growth narrative for TG Therapeutics. TG Therapeutics: The ‘Exit Velocity’ You Can’t Ignore (Rating Upgrade)
• Positive Sentiment: Media reported that Goldman Sachs sees substantial upside (~32% rally potential) as Briumvi sales accelerate, which supports a bullish case for continued revenue and earnings upside. TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally
• Positive Sentiment: HC Wainwright raised its Q4 2025 EPS estimate to $0.27 (from $0.20) and keeps a “Buy” rating with a $60 target — a clear near‑term analyst endorsement that can support upside. MarketBeat TGTX analyst note
• Positive Sentiment: HC Wainwright also raised FY2025 EPS to $2.89 (from $2.83), reflecting stronger near‑term earnings expectations tied to current product momentum. MarketBeat TGTX analyst note
• Neutral Sentiment: HC Wainwright published a set of long‑range forecasts (FY2026–FY2030, including FY2030 EPS of $3.96). These long‑horizon numbers frame upside potential but are model‑dependent and less immediately market‑moving. MarketBeat TGTX analyst note
• Negative Sentiment: Bank of America Securities initiated/maintained a “Sell” on TGTX, which is directly bearish and likely pressured the stock amid mixed optimism elsewhere. TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities
• Negative Sentiment: HC Wainwright trimmed several mid‑to‑longer‑term estimates (Q4 2026, FY2026–FY2029, FY2028–FY2029 down slightly), signaling some moderation in the firm’s prior growth assumptions and reducing upside in those years despite the persistent $60 target. MarketBeat TGTX analyst note

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.